Julaine (JULÄINE) Collagen Biostimulator: A Complete Guide

What is Poly-L-Lactic Acid (PLLA)?

PLLA is a synthetic, biocompatible and biodegradable polymer. It has been used safely in medicine for over 50 years in absorbable sutures, bone fixation pins and soft-tissue implants. When injected into the skin’s deeper layers, PLLA microspheres act as a scaffold that stimulates the body’s natural collagen-building processes.

After injection, the microspheres gradually dissolve over 9–12 months. During this time, they stimulate fibroblasts (the cells responsible for collagen production) to lay down new collagen fibres around the dissolving particles. This process is called neocollagenesis.

The key distinction is that PLLA does not add volume itself — it triggers your body to build new structural tissue. This means results are gradual and progressive, developing over weeks to months as collagen accumulates. The collagen produced is your own genuine tissue, not a synthetic material.

This is fundamentally different from hyaluronic acid fillers, which add immediate volume through gel injection. For a detailed breakdown, see our Julaine vs dermal fillers comparison.

Who is Julaine Suitable For?

Julaine is suitable for a broad range of patients, though the ideal candidate and expected outcomes vary by age group and skin condition. Understanding where you fit can help you form realistic expectations before your consultation.

Patients in their 30s

For patients in their thirties, collagen decline is underway but often not yet visibly advanced. At this stage, Julaine can serve as a preventive investment — stimulating collagen production before significant firmness loss becomes apparent. Patients in this group typically notice a subtle but meaningful improvement in skin firmness, resilience and overall radiance. It is an excellent option for those who want to stay ahead of the ageing process without resorting to volumising treatments they do not yet need.

Patients in their 40s

The forties are often where Julaine delivers its most striking results. At this stage, visible firmness loss is typically apparent — nasolabial folds deepen, early jowling may be starting, and neck texture begins to change. The skin still has strong regenerative capacity, meaning it responds well to biostimulation. Julaine can restore structural integrity to the mid-face and jawline while improving overall skin quality in a way that looks entirely natural.

Patients in their 50s and beyond

For patients over fifty, collagen loss is more advanced, and the skin’s regenerative capacity has slowed. Julaine can still produce meaningful improvement in skin firmness and quality, but expectations should be calibrated accordingly. In many cases, a combination approach works best — Julaine for collagen stimulation alongside other treatments such as Profhilo for hydration or dermal fillers for targeted volume restoration. Dr Langdon will discuss the most effective strategy during your consultation.

GLP-1 medication patients (“Ozempic face”)

Patients experiencing facial volume and skin quality changes from GLP-1 medications such as Ozempic, Wegovy or Mounjaro are increasingly seeking aesthetic treatment. The rapid subcutaneous fat loss associated with these medications can leave the face looking deflated, with loose skin and prominent folds. Because Julaine stimulates collagen production rather than simply replacing volume, it is well-suited for these patients — helping to rebuild the skin’s structural framework from within.

Who is Julaine not suitable for?

Julaine is not suitable during pregnancy or breastfeeding, for patients with active skin infection at the treatment site, or for those with certain autoimmune conditions that affect connective tissue. It is also not the right choice for anyone seeking an immediate, visible change — the results develop gradually over weeks and months. These considerations are fully assessed during your consultation.

What to Expect: Treatment Process and Recovery

Consultation

Every Julaine treatment at Berkshire Aesthetics begins with a thorough consultation. Dr Langdon assesses your skin quality, discusses your medical history, explores your goals and expectations, and explains all available alternatives. This consultation-first approach ensures that Julaine is the right treatment for you and that you have realistic expectations about the process and outcomes.

Treatment

The treatment itself takes approximately 30 to 45 minutes. Julaine is injected using a grid-like pattern that ensures even distribution across the treatment area. Anaesthetic is not usually required, as most patients find the procedure comfortable with only mild, brief discomfort at the injection points. The reconstituted product is injected into the deep dermis or subcutaneous layer depending on the area being treated.

Immediate aftercare

Aftercare for Julaine is minimal. You may experience mild redness, small bumps at the injection sites, and possible bruising, which typically resolves within 24 to 72 hours. Unlike Sculptra, no post-treatment massage is required — this is one of the key practical advantages of Julaine’s LaSynPro technology.

Results timeline

Results from Julaine develop gradually. Many patients notice an initial radiance and subtle improvement in skin quality at around 4 to 6 weeks after their first treatment. Progressive firmness improvement continues to develop over 3 to 6 months as new collagen is laid down. The gradual nature of the results is part of what makes Julaine so natural-looking — changes develop at a pace that looks entirely organic.

Treatment course

A typical Julaine treatment course involves 2 to 3 sessions, spaced 4 to 6 weeks apart. The exact number of sessions depends on the degree of collagen loss, the treatment areas, and your individual response. Dr Langdon will advise on the optimal number of sessions for your specific needs.

Longevity

Results from a full course of Julaine typically last 12 to 24 months for many patients. The collagen produced is your own tissue, so it persists as part of your skin’s structure. However, natural ageing continues, so maintenance treatments may be recommended to sustain optimal results. A maintenance plan is discussed at your review appointment following the initial course.

Safety, Regulation and Clinical Evidence

Julaine is CE-marked and MHRA approved for use in the UK, meaning it has undergone rigorous assessment for safety, quality and performance. The PLLA material class on which Julaine is based has been used safely in medicine for over 50 years across a range of applications including absorbable sutures and orthopaedic fixation devices.

One of the notable safety advantages of Julaine is the reduced risk of nodule formation compared to older PLLA formulations. The uniformity of the microspheres produced by LaSynPro technology means they distribute more evenly within tissue, minimising the risk of product aggregation that has historically been associated with palpable lumps. To date, there have been no reported cases of vascular occlusion with Julaine — an important safety consideration in any injectable treatment.

As with all injectable aesthetic treatments, the skill and experience of the practitioner is one of the most significant safety factors. Julaine should only be administered by a medically qualified professional — a doctor, dentist, or prescribing nurse — with specific training in biostimulator techniques. Treatment should ideally take place in a CQC-registered clinical setting where appropriate governance, hygiene standards, and emergency protocols are in place.